Parasite membrane phospholipids and membrane-embedded lipid biosynthetic enzymes

Parasite membrane phospholipids and their biosynthetic enzymes are essential for the structural integrity and replication of protozoan parasites like Plasmodium and Leishmania (Source: PMID 21923609). These organisms rely on the de novo synthesis of lipids such as phosphatidylcholine and phosphatidylethanolamine to support rapid cell division and membrane expansion during their life cycles (Source: PMID 15590771). The enzymes involved in these pathways, particularly those in the Kennedy pathway and the plant-like phosphoethanolamine methyltransferase (PMT) pathway, are often distinct from human enzymes, making them viable drug targets (Source: PMID 19185558). Therapeutic agents like miltefosine and albitiazolium exert their effects by either mimicking phospholipids to disrupt membrane function or by inhibiting specific biosynthetic steps like choline transport and phosphorylation (Source: PMID 24511041). Disruption of these lipid-related processes leads to impaired membrane biogenesis, altered signaling, and ultimately parasite death. Because these targets are fundamental to the parasite's survival, they are highly prioritized in the development of new antimalarial and antileishmanial therapies. However, the potential for host toxicity due to similarities in certain lipid metabolic steps necessitates careful design to ensure selective toxicity (Source: PMID 21923609). Clinical use of drugs targeting these pathways must also account for significant safety concerns, such as the known teratogenic potential of miltefosine (Source: PubChem CID 3599).

Other names

Parasite lipid metabolismProtozoan phospholipid biosynthetic pathwaysKennedy pathway enzymesPlasmodium lipid biosynthetic enzymes

Inhibition of de novo phospholipid biosynthetic pathways (such as the Kennedy pathway) and direct disruption of the parasite's membrane structural integrity and lipid-mediated signaling.